Do Statins Lower Triglycerides? How They Work

Statins do lower triglycerides, but the size of the drop depends almost entirely on how high your triglycerides are to begin with. In people with elevated levels above 250 mg/dL, statins can reduce triglycerides by roughly 20 to 45 percent. If your triglycerides are already in the normal range, you probably won’t see much change at all. That relationship between starting level and outcome is the single most important thing to understand about statins and triglycerides, and it shapes everything from which statin your doctor picks to whether you’ll need additional medication.

Your Starting Triglyceride Level Changes Everything

Statins are famous for lowering LDL cholesterol, and that remains their primary job. But researchers noticed early on that patients with high triglycerides were getting a secondary benefit. A study comparing multiple statins found that when baseline triglycerides exceeded 250 mg/dL, all statins produced significant, dose-dependent reductions of 22 to 45 percent. When triglycerides started below 150 mg/dL, there was no meaningful or dose-dependent triglyceride effect at all.¹ The in-between group, 150 to 250 mg/dL, saw moderate reductions.

This isn’t a minor footnote. It means the person sitting across from you in the waiting room might get a completely different triglyceride response from the same pill at the same dose. If your triglycerides are 120 mg/dL and your doctor prescribes a statin, don’t expect the triglyceride number on your next blood panel to move much. That statin is working on your LDL. But if you walked in with triglycerides of 300 mg/dL, you could see a substantial drop from the statin alone.

There’s an interesting mathematical regularity behind this. The ratio between the percentage drop in triglycerides and the percentage drop in LDL cholesterol stays roughly constant across different statins and doses for any given baseline triglyceride level.¹ In practical terms, the more powerfully a statin lowers your LDL, the more it will also lower your triglycerides, at least when your triglycerides are elevated to begin with.

How Statins Actually Bring Triglycerides Down

Statins block the liver enzyme responsible for making cholesterol. That’s the well-known mechanism that reduces LDL. But triglyceride lowering involves a different set of downstream effects, and it works through at least two pathways.

The first pathway involves clearing triglyceride-rich particles from the blood more quickly. Your body packages triglycerides into particles called VLDL in the liver, which then circulate and get broken down. Statins speed up the rate at which these VLDL particles are removed from circulation. Research on rosuvastatin showed that it significantly increased the clearance rate of VLDL particles in a dose-related fashion.² Atorvastatin showed a similar effect, roughly doubling the clearance rate of VLDL particles without changing how much the liver secreted.³

The second pathway involves a protein called apolipoprotein C-III (apoC-III for short), which acts like a brake on the system that clears triglyceride-rich particles. ApoC-III inhibits an enzyme called lipoprotein lipase, which is the main workhorse for breaking down triglycerides in circulation. Research on simvastatin found that it decreased both the gene expression and blood levels of apoC-III while simultaneously boosting lipoprotein lipase activity in fat tissue and the heart.⁴ A meta-analysis of six randomized trials confirmed this: statin therapy significantly reduced circulating apoC-III levels across the board.⁵ So statins are essentially releasing the brake while also speeding up the engine that clears triglycerides.

There’s also some evidence that statins reduce the liver’s production of VLDL particles over longer time frames. In laboratory studies, statins caused a generalized 20 to 40 percent decrease in the secretion of VLDL components after 24 hours of treatment, though this effect took time to develop and wasn’t apparent within the first couple of hours.⁶ This dual action, producing fewer triglyceride-rich particles and clearing existing ones faster, explains why the triglyceride effect grows more pronounced as you look at patients who had more of those particles to begin with.

Which Statins Are Strongest for Triglycerides

Not all statins are created equal here. A large meta-analysis compared rosuvastatin, atorvastatin, and simvastatin head-to-head in patients with elevated triglycerides. Mean triglyceride reductions across these drugs ranged from about 15 to 31 percent. Rosuvastatin at 10 mg produced significantly greater triglyceride reductions than atorvastatin at 10 mg. At higher doses of 20 and 40 mg, rosuvastatin and atorvastatin performed similarly. But rosuvastatin at any dose from 10 to 40 mg beat equal or even double doses of simvastatin.⁷

The practical takeaway: rosuvastatin and atorvastatin are the heavy hitters. If your doctor is prescribing a statin partly because your triglycerides are elevated, these two are the likely choices, particularly rosuvastatin at moderate doses or atorvastatin at higher doses. Simvastatin, pravastatin, and the older statins still lower triglycerides, but you might need a higher dose or still end up needing a second drug. That said, because the triglyceride-to-LDL reduction ratio holds fairly steady, any statin that aggressively lowers your LDL will also make a dent in triglycerides if they were elevated.⁸

What Statins Do to Remnant Particles

Triglyceride numbers on a standard blood panel only tell part of the story. When triglyceride-rich particles are partially broken down in the bloodstream, they leave behind smaller remnant particles that are increasingly recognized as a cardiovascular threat in their own right. Intensive statin therapy with either atorvastatin or rosuvastatin reduced remnant lipoprotein cholesterol by roughly 59 to 62 percent, a substantially larger proportional drop than the roughly 28 to 33 percent reduction in total triglycerides seen in the same patients.⁹ The statins also lowered apoB-48, a protein carried specifically by particles that originate from dietary fat absorption, by about a third.

This matters because remnant particles can penetrate artery walls and contribute to plaque buildup. The fact that statins reduce remnants proportionally more than they reduce raw triglyceride numbers suggests the standard blood panel may understate how much cardiovascular benefit the statin is providing on the triglyceride front.

How Statins Compare to Other Triglyceride-Lowering Drugs

If triglycerides are your primary concern, statins are not the most powerful option. Fibrates, the traditional triglyceride-lowering drug class, beat statins at this specific job. A systematic review and meta-analysis of head-to-head trials found that fibrates reduced triglycerides about 15 percentage points more than statins did. Fibrates also raised HDL cholesterol more than statins. But statins dominated on every other lipid measure: they lowered LDL cholesterol by about 20 percentage points more and lowered non-HDL cholesterol by roughly 21 percentage points more than fibrates.¹⁰

That tradeoff is why statins remain the first-line drug for most patients with mixed lipid problems. LDL cholesterol has the largest and most consistent evidence base for driving heart disease risk, so getting it down is usually the first priority. Fibrates fill a specific niche: patients whose primary lipid problem is very high triglycerides with low HDL, and who either cannot tolerate statins or need additional help on top of one.

Omega-3 fatty acids, especially the prescription-strength formulations, are the other major triglyceride-lowering option. Adding omega-3s to a statin can improve the overall lipid profile beyond what the statin achieves alone.¹¹ But the real attention-grabber was the REDUCE-IT trial, which tested icosapent ethyl (a purified EPA supplement) in patients already on statins who still had elevated triglycerides. Major cardiovascular events dropped by 25 percent in the group receiving icosapent ethyl compared to placebo.¹² Cardiovascular death rates also fell. This was a landmark finding because it showed that attacking residual triglyceride elevation on top of statin therapy could produce real clinical benefits, not just better-looking lab numbers.

When Statins Alone Aren’t Enough

For people with very high triglycerides, particularly above 500 mg/dL, statins alone rarely do enough. Those levels raise the risk of pancreatitis, and doctors typically reach for fibrates or prescription omega-3s as the primary treatment, sometimes alongside a statin. The combination of a statin and fenofibrate is considered the safer pairing within the fibrate class. In patients with diabetes and mixed lipid problems, combining simvastatin with fenofibrate was more effective at shifting the lipoprotein profile than either drug alone, particularly at reducing the small, dense particles that form when triglycerides are elevated.¹³

Clinical trials have suggested that fibrates reduce major cardiovascular events primarily in the subset of patients who have both high triglycerides and low HDL, and this finding has held when fenofibrate was added to statin therapy.¹⁴ For patients outside that subgroup, adding a fibrate may improve lab numbers without clearly reducing heart attacks or strokes.

The icosapent ethyl data from REDUCE-IT changed the calculus for combination approaches. The National Lipid Association issued a scientific statement supporting its use in statin-treated patients with elevated triglycerides who remained at high or very high cardiovascular risk, based on the 25 percent reduction in major adverse cardiovascular events.¹⁵ This option sits in a different safety category than statin-fibrate combinations, which carry additional muscle-related risks.

Safety Considerations for Statin-Fibrate Combinations

If your doctor suggests adding a fibrate to your statin, the choice of fibrate matters. Combining a statin with gemfibrozil raises the risk of myopathy and, in rare cases, rhabdomyolysis, a serious condition where muscle tissue breaks down. This happens because gemfibrozil interferes with the way the body processes statins, causing statin levels in the blood to climb higher than intended.¹⁶ Fenofibrate does not cause this same interaction, which is why it is the preferred fibrate for combination therapy.¹⁷

Other factors can compound the risk of muscle problems: kidney impairment, older age, certain other medications that also raise statin blood levels, and using higher statin doses. If you’re on a statin-fibrate combination and develop unexplained muscle pain or weakness, that warrants a prompt conversation with your doctor rather than a wait-and-see approach.

The Residual Risk Problem

One of the more sobering findings in cardiovascular medicine is that even patients who hit their LDL targets on statins can still have heart attacks and strokes if their triglycerides remain elevated. A large contemporary study of statin-treated patients found that those with elevated triglycerides faced a higher risk of cardiovascular events.¹⁸ This persistent risk, often called “residual cardiovascular risk,” is one of the reasons triglyceride management has gained more clinical attention in recent years.

The evidence is particularly clear in patients with diabetes. Among diabetic patients whose LDL was well-controlled on a statin, those with high triglycerides still experienced more cardiovascular events than those with normal triglycerides. The researchers controlled for other cardiometabolic risk factors, suggesting that the elevated triglyceride levels themselves were contributing to the excess risk.¹⁹ A separate study in patients with established cardiovascular disease confirmed the pattern: elevated triglycerides were linked to higher residual risk regardless of whether patients had achieved guideline-recommended lipid targets and regardless of how intensive their lipid-lowering therapy was.²⁰

This is the gap that newer combination strategies are trying to fill. A statin gets your LDL down. But if your triglycerides stay stubbornly high, additional treatment may be needed to address that separate layer of risk.

Beyond Fasting Levels

Standard lipid panels measure triglycerides after an overnight fast, but your body spends most of the day in a fed state, processing fat from meals. These postprandial triglyceride spikes can be large, and there is growing recognition that they contribute to cardiovascular risk independently of fasting levels. Animal research has shown that certain statins can blunt these after-meal surges. In a rat model, pitavastatin suppressed the secretion of triglyceride-carrying particles from the gut by about 40 percent after a single dose, and reduced the overall postprandial triglyceride exposure (measured as the area under the curve over 12 hours) by more than half. Atorvastatin produced a similar but smaller effect, and the mechanism appeared to involve reduced activity of a protein in the intestine that helps package dietary fat for absorption.²¹

Human data is more modest. A study in overweight adults with high cholesterol found that statin therapy alone reduced postprandial triglycerides compared to no treatment. However, adding an exercise session on top of the statin did not produce any additional reduction in the post-meal triglyceride spike, which surprised the researchers.²² Exercise has well-established triglyceride-lowering effects on its own, but this study suggests that in people already taking a statin, a single bout of exercise may not stack additional benefit on the postprandial response. The long-term effects of regular exercise combined with statin therapy on triglyceride metabolism are likely more complex and remain an active area of research.

Emerging Approaches That Target Triglycerides More Directly

The understanding that apoC-III acts as a brake on triglyceride clearance, the same protein that statins modestly reduce, has opened the door for drugs designed to target it much more aggressively. Experimental therapies including antisense oligonucleotides aimed at apoC-III, as well as drugs targeting another regulatory protein called ANGPTL3, are being developed to lower triglycerides far more dramatically than statins or even fibrates can manage.²³ These next-generation drugs can slash triglycerides by 50 percent or more in clinical trials, making them particularly promising for patients with severe genetic forms of hypertriglyceridemia who get insufficient benefit from existing medications.

Whether these dramatic triglyceride reductions translate into fewer heart attacks and strokes is the question that ongoing trials are trying to answer. The REDUCE-IT results with icosapent ethyl showed that the concept works, at least with purified EPA. But the mechanisms behind EPA’s cardiovascular benefits appear to extend beyond simple triglyceride lowering, making it difficult to extrapolate directly to drugs that attack triglycerides through completely different pathways. For now, statins remain the foundation of lipid therapy for most patients, with their triglyceride-lowering effect as a useful but secondary benefit that grows more relevant as baseline levels climb higher.